

IAP20 Rec'd PCT/JP 17 FEB 2006

Amendment of the claims under PCT Article 19(1)

What is claimed is:

1. A method for examining colorectal cancer and colorectal adenoma comprising
5 assaying the reactivity of an antibody to tissues, body fluid or feces of patients, or
extracts thereof, wherein said antibodies react with such antigen that is present in
cells expressing HEC-GlcNAc6ST gene encoding GlcNAc-6-sulfotransferase and that
is absent or almost absent in cells expressing GlcNAc6ST-1 or I-GlcNAc6ST gene.
2. The method of claim 1, wherein said antigen is present in cells transduced with
10 HEC-GlcNAc6ST gene and is absent or almost absent in cells transduced with
GlcNAc6ST-1 gene or I-GlcNAc6ST gene.
3. The method of claim 1 or 2, wherein said antigen comprises the sugar residues
expressed by the following formula:
R1-Gal β 1-3/4(SO₃-6) GlcNAc β 1-R2
15 where, R1 represents sugar residues added by other enzymes and is not limited in
structure. Gal β represents β galactose, GlcNAc β represents β N-acetylglucosamine,
Gal β 1-3/4 represents binding of 1 position of Gal β and 3 position and/or 4 position of
GlcNAc β , (SO₃-6) represents addition of a sulfate group to 6 position of GlcNAc β , R2
represents -3GalNAc α , -3Gal β or -2Man α and binds to 1 position of GlcNAc β .
- 20 4. The method of any one of claims 1 to 3, wherein said antibody is MECA-79
antibody (Pharmingen, catalog No. 09961D).
5. A method for examining colorectal cancer and colorectal adenoma comprising
assaying the reactivity of MECA-79 antibody or its equivalent with tissues, body
fluid, feces or extract thereof of test subjects.
- 25 6. The method of any one of claims 1 to 5 comprising reacting a labeled probe to said
antibody and assaying the label qualitatively or quantitatively.
7. (amended) An examination reagent for colorectal cancer and colorectal adenoma
comprising, as a major component, an antibody (including MECA-79 antibody)
reacting specifically with an antigen carrying sugar residues, which is present in
30 cells expressing HEC-GlcNAc6ST gene and is absent or almost absent in cells
expressing GlcNAc6ST-1 or GlcNAc6ST gene.
8. (amended)

An examination reagent for colorectal cancer and colorectal adenoma comprising, as a major component, an antibody (including MECA-79 antibody) reacting specifically with an antigen carrying sugar residues, which is present in cells transduced with HEC-GlcNAc6ST gene and is absent or almost absent in cells transduced with
5 GlcNAc6ST-1 or GlcNAc6ST gene.

9. (amended)

An examination reagent for colorectal cancer and colorectal adenoma comprising, as a major component, an antibody (including MECA-79 antibody) reacting specifically with an antigen carrying sugar residues, which are present in tissues, body fluid or
10 feces of patients with colorectal cancer and colorectal adenoma and expressed by the following general formula:

$R1-Gal \beta 1-3/4 (SO_3-6) GlcNAc \beta 1-R2$

where, R1 represents sugar residues added by other enzymes and is not limited in structure. Gal β represents β galactose, GlcNAc β represents β N-acetylglucosamine,
15 Gal $\beta 1-3/4$ represents binding of 1 position of Gal β and 3 position and/or 4 position of GlcNAc β , (SO_3-6) represents addition of a sulfate group to 6 position of GlcNAc β , R2 represents $-3GalNAc \alpha$, $-3Gal \beta$ or $-2Man \alpha$ and binds to 1 position of GlcNAc β .

10. (amended) An examination reagent for colorectal cancer and colorectal adenoma comprising MECA-79 antibody as a major component.